blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2844289

EP2844289 - MOLECULES WITH REDUCED EFFECTOR FUNCTION AND EXTENDED HALF-LIVES, COMPOSITIONS, AND USES THEREOF [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  03.07.2020
Database last updated on 28.03.2026
FormerThe patent has been granted
Status updated on  14.06.2019
FormerGrant of patent is intended
Status updated on  05.02.2019
FormerExamination is in progress
Status updated on  08.12.2017
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
MedImmune, LLC
One MedImmune Way
Gaithersburg, MD 20878 / US
[2015/11]
Inventor(s)01 / TSUI, Ping
c/o Medimmune LLC
One Medimmune Way
Gaithersburg, MD 20878 / US
02 / BORROK, Martin
c/o Medimmune LLC
One Medimmune Way
Gaithersburg, MD 20878 / US
03 / DALL'ACQUA, William
c/o Medimmune LLC
One Medimmune Way
Gaithersburg, MD 20878 / US
 [2015/11]
Representative(s)AstraZeneca Intellectual Property
Eastbrook House
Shaftesbury Road
Cambridge CB2 8BF / GB
[N/P]
Former [2019/29]AstraZeneca
Milstein Building
Granta Park
Cambridge CB21 6GH / GB
Former [2015/11]Winter, Christopher Spencer
MedImmune Limited
Milstein Building
Granta Park
Cambridge
CB21 6GH / GB
Application number, filing date13784604.417.04.2013
[2019/29]
WO2013US36872
Priority number, dateUS201261640327P30.04.2012         Original published format: US 201261640327 P
[2015/11]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2013165690
Date:07.11.2013
Language:EN
[2013/45]
Type: A1 Application with search report 
No.:EP2844289
Date:11.03.2015
Language:EN
The application published by WIPO in one of the EPO official languages on 07.11.2013 takes the place of the publication of the European patent application.
[2015/11]
Type: B1 Patent specification 
No.:EP2844289
Date:17.07.2019
Language:EN
[2019/29]
Search report(s)International search report - published on:US07.11.2013
(Supplementary) European search report - dispatched on:EP03.11.2015
ClassificationIPC:C07K16/18, C07K16/28, C07K16/10, A61K39/395, C12P21/08
[2015/49]
CPC:
C07K16/2887 (EP,US); A61K39/39591 (EP,US); A61P43/00 (EP);
C07K16/11 (EP,US); C07K16/18 (EP,US); C07K16/2866 (EP,US);
C07K2317/52 (EP,US); C07K2317/524 (EP,US); C07K2317/54 (US);
C07K2317/55 (US); C07K2317/71 (EP,US); C07K2317/94 (EP,US) (-)
Former IPC [2015/11]A61K39/395, C12P21/08, C07K16/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2015/11]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:MOLEKÜLE MIT VERMINDERTER EFFEKTORFUNKTION UND VERLÄNGERTER HALBWERTZEIT SOWIE ZUSAMMENSETZUNGEN DAMIT UND VERWENDUNGEN DAVON[2015/11]
English:MOLECULES WITH REDUCED EFFECTOR FUNCTION AND EXTENDED HALF-LIVES, COMPOSITIONS, AND USES THEREOF[2015/11]
French:MOLÉCULES AYANT UNE FONCTION EFFECTRICE RÉDUITE ET DES DEMI-VIES ALLONGÉES, COMPOSITIONS ET UTILISATIONS DE CELLES-CI[2015/11]
Entry into regional phase27.11.2014National basic fee paid 
27.11.2014Search fee paid 
27.11.2014Designation fee(s) paid 
27.11.2014Examination fee paid 
Examination procedure27.11.2014Examination requested  [2015/11]
27.05.2016Amendment by applicant (claims and/or description)
07.12.2017Despatch of a communication from the examining division (Time limit: M06)
15.06.2018Reply to a communication from the examining division
06.02.2019Communication of intention to grant the patent
06.06.2019Fee for grant paid
06.06.2019Fee for publishing/printing paid
06.06.2019Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  07.12.2017
Opposition(s)03.06.2020No opposition filed within time limit [2020/32]
Fees paidRenewal fee
27.04.2015Renewal fee patent year 03
27.04.2016Renewal fee patent year 04
10.04.2017Renewal fee patent year 05
11.04.2018Renewal fee patent year 06
30.04.2019Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU17.04.2013
AL17.07.2019
AT17.07.2019
CY17.07.2019
CZ17.07.2019
DK17.07.2019
EE17.07.2019
FI17.07.2019
HR17.07.2019
LT17.07.2019
LV17.07.2019
MC17.07.2019
MK17.07.2019
MT17.07.2019
PL17.07.2019
RO17.07.2019
RS17.07.2019
SI17.07.2019
SK17.07.2019
SM17.07.2019
BG17.10.2019
NO17.10.2019
GR18.10.2019
IS17.11.2019
PT18.11.2019
IE17.04.2020
LU17.04.2020
BE30.04.2020
[2022/32]
Former [2022/27]HU17.04.2013
AL17.07.2019
AT17.07.2019
CY17.07.2019
CZ17.07.2019
DK17.07.2019
EE17.07.2019
FI17.07.2019
HR17.07.2019
LT17.07.2019
LV17.07.2019
MC17.07.2019
MT17.07.2019
PL17.07.2019
RO17.07.2019
RS17.07.2019
SI17.07.2019
SK17.07.2019
SM17.07.2019
BG17.10.2019
NO17.10.2019
GR18.10.2019
IS17.11.2019
PT18.11.2019
IE17.04.2020
LU17.04.2020
BE30.04.2020
Former [2021/20]AL17.07.2019
AT17.07.2019
CZ17.07.2019
DK17.07.2019
EE17.07.2019
FI17.07.2019
HR17.07.2019
LT17.07.2019
LV17.07.2019
MC17.07.2019
PL17.07.2019
RO17.07.2019
RS17.07.2019
SI17.07.2019
SK17.07.2019
SM17.07.2019
BG17.10.2019
NO17.10.2019
GR18.10.2019
IS17.11.2019
PT18.11.2019
IE17.04.2020
LU17.04.2020
BE30.04.2020
Former [2021/12]AL17.07.2019
AT17.07.2019
CZ17.07.2019
DK17.07.2019
EE17.07.2019
FI17.07.2019
HR17.07.2019
LT17.07.2019
LV17.07.2019
MC17.07.2019
PL17.07.2019
RO17.07.2019
RS17.07.2019
SI17.07.2019
SK17.07.2019
SM17.07.2019
BG17.10.2019
NO17.10.2019
GR18.10.2019
IS17.11.2019
PT18.11.2019
LU17.04.2020
BE30.04.2020
Former [2021/08]AL17.07.2019
AT17.07.2019
CZ17.07.2019
DK17.07.2019
EE17.07.2019
FI17.07.2019
HR17.07.2019
LT17.07.2019
LV17.07.2019
MC17.07.2019
PL17.07.2019
RO17.07.2019
RS17.07.2019
SI17.07.2019
SK17.07.2019
SM17.07.2019
BG17.10.2019
NO17.10.2019
GR18.10.2019
IS17.11.2019
PT18.11.2019
LU17.04.2020
Former [2020/52]AL17.07.2019
AT17.07.2019
CZ17.07.2019
DK17.07.2019
EE17.07.2019
FI17.07.2019
HR17.07.2019
LT17.07.2019
LV17.07.2019
MC17.07.2019
PL17.07.2019
RO17.07.2019
RS17.07.2019
SI17.07.2019
SK17.07.2019
SM17.07.2019
BG17.10.2019
NO17.10.2019
GR18.10.2019
IS17.11.2019
PT18.11.2019
Former [2020/37]AL17.07.2019
AT17.07.2019
CZ17.07.2019
DK17.07.2019
EE17.07.2019
FI17.07.2019
HR17.07.2019
LT17.07.2019
LV17.07.2019
PL17.07.2019
RO17.07.2019
RS17.07.2019
SI17.07.2019
SK17.07.2019
SM17.07.2019
BG17.10.2019
NO17.10.2019
GR18.10.2019
IS17.11.2019
PT18.11.2019
Former [2020/36]AL17.07.2019
AT17.07.2019
CZ17.07.2019
DK17.07.2019
EE17.07.2019
FI17.07.2019
HR17.07.2019
LT17.07.2019
LV17.07.2019
PL17.07.2019
RO17.07.2019
RS17.07.2019
SK17.07.2019
SM17.07.2019
BG17.10.2019
NO17.10.2019
GR18.10.2019
IS17.11.2019
PT18.11.2019
Former [2020/27]AL17.07.2019
AT17.07.2019
CZ17.07.2019
DK17.07.2019
EE17.07.2019
FI17.07.2019
HR17.07.2019
LT17.07.2019
LV17.07.2019
PL17.07.2019
RO17.07.2019
RS17.07.2019
SK17.07.2019
SM17.07.2019
BG17.10.2019
NO17.10.2019
GR18.10.2019
PT18.11.2019
IS24.02.2020
Former [2020/25]AL17.07.2019
AT17.07.2019
CZ17.07.2019
DK17.07.2019
EE17.07.2019
FI17.07.2019
HR17.07.2019
LT17.07.2019
LV17.07.2019
PL17.07.2019
RO17.07.2019
RS17.07.2019
SK17.07.2019
BG17.10.2019
NO17.10.2019
GR18.10.2019
PT18.11.2019
IS24.02.2020
Former [2020/24]AL17.07.2019
AT17.07.2019
DK17.07.2019
EE17.07.2019
FI17.07.2019
HR17.07.2019
LT17.07.2019
LV17.07.2019
PL17.07.2019
RO17.07.2019
RS17.07.2019
BG17.10.2019
NO17.10.2019
GR18.10.2019
PT18.11.2019
IS24.02.2020
Former [2020/23]AL17.07.2019
AT17.07.2019
DK17.07.2019
EE17.07.2019
FI17.07.2019
HR17.07.2019
LT17.07.2019
LV17.07.2019
PL17.07.2019
RO17.07.2019
RS17.07.2019
BG17.10.2019
NO17.10.2019
GR18.10.2019
IS17.11.2019
PT18.11.2019
Former [2020/22]AL17.07.2019
AT17.07.2019
DK17.07.2019
EE17.07.2019
FI17.07.2019
HR17.07.2019
LT17.07.2019
LV17.07.2019
RS17.07.2019
BG17.10.2019
NO17.10.2019
GR18.10.2019
IS17.11.2019
PT18.11.2019
Former [2020/15]AL17.07.2019
AT17.07.2019
FI17.07.2019
HR17.07.2019
LT17.07.2019
LV17.07.2019
RS17.07.2019
BG17.10.2019
NO17.10.2019
GR18.10.2019
IS17.11.2019
PT18.11.2019
Former [2020/12]AT17.07.2019
FI17.07.2019
HR17.07.2019
LT17.07.2019
LV17.07.2019
RS17.07.2019
BG17.10.2019
NO17.10.2019
GR18.10.2019
IS17.11.2019
PT18.11.2019
Former [2020/11]AT17.07.2019
FI17.07.2019
HR17.07.2019
LT17.07.2019
LV17.07.2019
RS17.07.2019
BG17.10.2019
NO17.10.2019
GR18.10.2019
PT18.11.2019
Former [2020/10]AT17.07.2019
FI17.07.2019
LT17.07.2019
BG17.10.2019
NO17.10.2019
PT18.11.2019
Former [2020/09]FI17.07.2019
LT17.07.2019
NO17.10.2019
Former [2020/08]LT17.07.2019
NO17.10.2019
Documents cited:Search[I] WO2009003019  (MEDIMMUNE LLC et al.) [I] 1-17 * page 118 - page 119; example 5 * * claims 7, 8, 12 *
 [A] US2007009523  (PRESTA LEONARD et al.) [A] 1-17 * abstract * * page 29; example 2 * * page 29, column l, paragraph 0350 * * page 30; table 3 * * page 31; table 4 * * page 29, paragraph 0350 *
 [A]   THOMMESEN JOHN E ET AL: "Lysine 322 in the human IgG3 CH2 domain is crucial for antibody dependent complement activation", MOLECULAR IMMUNOLOGY, PERGAMON, GB, vol. 37, no. 16, 1 November 2001 (2001-11-01), pages 995 - 1004, XP002522213, ISSN: 0161-5890, [retrieved on 20010531], DOI: 10.1016/S0161-5890(01)00010-4 [A] 1-17 * abstract * * page 1003, column l, paragraph 1 *

DOI:   http://dx.doi.org/10.1016/S0161-5890(01)00010-4
 [A]   DALL'ACQUA W F ET AL: "Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn)", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 281, no. 33, 21 June 2006 (2006-06-21), pages 23514 - 23524, XP002404904, ISSN: 0021-9258, DOI: 10.1074/JBC.M604292200 [A] 1-17 * abstract *

DOI:   http://dx.doi.org/10.1074/jbc.M604292200
 [A]   KUO T T ET AL: "Neonatal Fc receptor and IgG-based therapeutics", MABS, LANDES BIOSCIENCE, US, vol. 3, no. 5, 1 September 2011 (2011-09-01), pages 422 - 430, XP002738428, ISSN: 1942-0862, [retrieved on 20110901], DOI: 10.4161/MABS.3.5.16983 [A] 1-17 * the whole document *

DOI:   http://dx.doi.org/10.4161/mabs.3.5.16983
 [A]   PRESTA ET AL: "Molecular engineering and design of therapeutic antibodies", CURRENT OPINION IN IMMUNOLOGY, ELSEVIER, OXFORD, GB, vol. 20, no. 4, 1 August 2008 (2008-08-01), pages 460 - 470, XP025771205, ISSN: 0952-7915, [retrieved on 20080806], DOI: 10.1016/J.COI.2008.06.012 [A] 1-17 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.coi.2008.06.012
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.